Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
CC transcript

Asterias Biotherapeutics, Inc. (AST) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/20/2019 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
03/20/2019 EFFECT Form EFFECT - Notice of Effectiveness:
03/20/2019 EFFECT Form EFFECT - Notice of Effectiveness:
03/20/2019 EFFECT Form EFFECT - Notice of Effectiveness:
03/14/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/14/2019 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/14/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/14/2019 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/14/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/14/2019 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/14/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/12/2019 4 BROADWOOD PARTNERS, L.P. (See Remarks Below) has filed a Form 4 on Asterias Biotherapeutics, Inc.
Txns: Disposed of 5,292,156 shares @ $0
03/12/2019 SC 13D/A BROADWOOD PARTNERS, L.P. reports a 0% stake in Asterias Biotherapeutics, Inc.
03/08/2019 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of Asterias Biotherapeutics, Inc",
"Amended and Restated Bylaws of Asterias Biotherapeutics, Inc"
03/08/2019 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/05/2019 4 Wirth Edward (Chief Medical Officer) has filed a Form 4 on Asterias Biotherapeutics, Inc.
Txns: Granted 156,452 shares @ $0
Paid exercise price by delivering 48,826 shares @ $0.95, valued at $46.4k
03/05/2019 4 Mulroy Michael H. (President and CEO) has filed a Form 4 on Asterias Biotherapeutics, Inc.
Txns: Granted 252,606 shares @ $0
Paid exercise price by delivering 76,588 shares @ $0.95, valued at $72.8k
03/05/2019 4 Chavez Ryan Daniel (CFO and General Counsel) has filed a Form 4 on Asterias Biotherapeutics, Inc.
Txns: Granted 145,263 shares @ $0
Paid exercise price by delivering 44,471 shares @ $0.95, valued at $42.2k
03/01/2019 8-K Quarterly results
03/01/2019 425 Form 425 - Prospectuses and communications, business combinations:
02/28/2019 425 Form 425 - Prospectuses and communications, business combinations:
02/04/2019 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
01/24/2019 425 Form 425 - Prospectuses and communications, business combinations:
01/24/2019 GN Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
01/04/2019 4 Chavez Ryan Daniel (CFO and General Counsel) has filed a Form 4 on Asterias Biotherapeutics, Inc.
Txns: Paid exercise price by delivering 20,440 shares @ $0.68, valued at $13.9k
01/04/2019 4 Wirth Edward (Chief Medical Officer) has filed a Form 4 on Asterias Biotherapeutics, Inc.
Txns: Paid exercise price by delivering 20,440 shares @ $0.68, valued at $13.9k
01/04/2019 GN BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
12/06/2018 425 Form 425 - Prospectuses and communications, business combinations:
12/06/2018 425 Form 425 - Prospectuses and communications, business combinations:
12/04/2018 425 Form 425 - Prospectuses and communications, business combinations:
11/27/2018 GN Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung Cancer
11/09/2018 425 Form 425 - Prospectuses and communications, business combinations:
11/09/2018 10-Q Quarterly Report for the period ended September 30, 2018
11/08/2018 425 Form 425 - Prospectuses and communications, business combinations:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy